Medidata Enhances RBM with Centralized Tool
Medidata announced the availability is enriched solution for risk-based monitoring.
Medidata announced the availability is enriched solution for risk-based monitoring (RBM). Acquired from Patient Profiles, the new offering will be integrated into the Medidata Clinical Cloud® as part of Medidata RBM. A comprehensive, systematic approach to risk-based monitoring, Medidata RBM includes a robust combination of technology, analytics and hands-on strategic consulting services that enable life science organizations to quickly realize the quality, cost and timeline benefits of a RBM program.
Through the automated review of clinical data captured in Medidata’s cloud-based electronic data capture and management system (Medidata Rave®), the addition of Patient Profiles makes Medidata RBM the first cloud-based solution to provide centralized monitoring analytics using both operational data (e.g., key risk indicators, such as adverse event rates and query cycle times) and patient data.
Read the full release here.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
